Target intelligence / Profile preview

Transcription factor CP2-like 1 (TFCP2L1)

Target
TFCP2L1
Molecular classification
Transcription factor
01

Overview

Transcription factor CP2-like 1 (TFCP2L1) is a member of the CP2 subfamily within the LSF/Grainyhead family of transcription factors[1][3]. It is critical for maintaining pluripotency and self-renewal in embryonic stem cells, primarily via direct regulation of target genes such as ESRRB and KLF4, and is necessary for normal development of tissues like the kidney and salivary gland[3][4][5]. In adult tissues, TFCP2L1 coordinates the development of intercalated and principal cells in the renal collecting ducts, participating in acid-base and salt-water homeostasis by regulating the expression of V-ATPase complex subunits and Notch signaling intermediates[1][5]. Beyond development, abnormal TFCP2L1 activity is linked to cancer stem cell maintenance and poor prognosis in cancers such as hepatocellular carcinoma, where it may promote resistance to targeted therapies, and in renal cancers where deregulation contributes to oncogenic reprogramming and tumor aggressiveness[2][3].

Other names
CRTR1LBP9CRTR-1LBP-9CP2-related transcriptional repressor 1transcription factor LBP-9
02

Mechanism of action

Inhibition of transcription factor activity attenuates cancer stem cell stemness and enhances chemosensitivity

03

Biological functions

Maintenance of pluripotency and self-renewal in embryonic stem cellsRegulation of transcription by RNA polymerase IIRegulation of cell differentiation (notably in kidney collecting ducts and embryonic stem cells)Regulation of Notch signaling via JAG1 expressionTissue-specific transcriptional regulation (including placenta and kidney)
04

Disease associations

Cancer (notably hepatocellular carcinoma, bladder cancer, renal medullary carcinoma)Chronic kidney diseaseFraser syndrome 1
05

Safety considerations

None specifically reported for therapeutic targeting; general concerns would revolve around impacting stem cell pluripotency and tissue development if broadly inhibited
06

Interacting drugs

Ti3 (experimental small molecule inhibitor in hepatocellular carcinoma studies)
07

Biomarkers

Elevated TFCP2L1 as a biomarker of cancer stemness and poor prognosis in hepatocellular carcinoma

Beyond the preview

Go deeper on Transcription factor CP2-like 1 (TFCP2L1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transcription factor CP2-like 1 (TFCP2L1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call